Literature DB >> 19648552

Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D.

Garry R Barton1, Jo Hodgekins, Miranda Mugford, Peter B Jones, Tim Croudace, David Fowler.   

Abstract

BACKGROUND: The UK National Institute for Health and Clinical Excellence (NICE) has recommended that cost-effectiveness analysis includes the EQ-5D; however, this is often not implemented in the area of mental health. AIMS: To assess the appropriateness of using the EQ-5D to measure improvements in mental health.
METHOD: Seventy-seven participants with psychosis were rated according to the EQ-5D and seven measures of mental health at both pre- and post-intervention. To assess construct validity we compared the (pre-intervention) mean EQ-5D scores for those with milder and more severe scores, according to each of the seven measures. To assess responsiveness we estimated the mean EQ-5D change score for those who improved (post-intervention), according to each of the measures.
RESULTS: The mean EQ-5D score was more favourable for both those with milder scores (mean difference: 0.044 to 0.301) and for those who improved post-intervention (mean change: 0.029 to 0.117).
CONCLUSIONS: This suggests the EQ-5D should be considered for use in future cost-effectiveness studies in the area of mental health.

Entities:  

Mesh:

Year:  2009        PMID: 19648552     DOI: 10.1192/bjp.bp.108.057380

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  16 in total

Review 1.  A review and critique of studies reporting utility values for schizophrenia-related health states.

Authors:  Ifigeneia Mavranezouli
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Quantifying quality of life and disability of patients with advanced schistosomiasis japonica.

Authors:  Tie-Wu Jia; Jürg Utzinger; Yao Deng; Kun Yang; Yi-Yi Li; Jin-Huan Zhu; Charles H King; Xiao-Nong Zhou
Journal:  PLoS Negl Trop Dis       Date:  2011-02-15

Review 3.  How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review.

Authors:  Diana Papaioannou; John Brazier; Glenys Parry
Journal:  Value Health       Date:  2011-07-28       Impact factor: 5.725

4.  Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ).

Authors:  Ina Zschocke; Ulrich Mrowietz; Annett Lotzin; Eleni Karakasili; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2014-02-08       Impact factor: 3.017

5.  Integrating Qualitative and Quantitative Data in the Development of Outcome Measures: The Case of the Recovering Quality of Life (ReQoL) Measures in Mental Health Populations.

Authors:  Anju Devianee Keetharuth; Elizabeth Taylor Buck; Catherine Acquadro; Katrin Conway; Janice Connell; Michael Barkham; Jill Carlton; Thomas Ricketts; Rosemary Barber; John Brazier
Journal:  Int J Environ Res Public Health       Date:  2018-06-26       Impact factor: 3.390

6.  Proxy WHO Disability Assessment Schedule 2.0 Is Clinically Useful for Assessing Psychosocial Functioning in Severe Mental Illness.

Authors:  Anne B Koopmans; Daphne van Hoeken; Diana E Clarke; David J Vinkers; Peter N van Harten; Hans W Hoek
Journal:  Front Psychiatry       Date:  2020-04-15       Impact factor: 4.157

7.  Comparing the performance of the EQ-5D and SF-6D when measuring the benefits of alleviating knee pain.

Authors:  Garry R Barton; Tracey H Sach; Anthony J Avery; Michael Doherty; Claire Jenkinson; Kenneth R Muir
Journal:  Cost Eff Resour Alloc       Date:  2009-07-17

Review 8.  Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2018-10-24

9.  interRAI Subjective Quality of Life Scale for Mental Health and Addiction Settings: A Self-Reported Measure Developed From a Multi-National Study.

Authors:  Hao Luo; Alice Hirdes; Jyrki Heikkilä; Kathleen De Cuyper; Chantal Van Audenhove; Margaret Saari; John P Hirdes
Journal:  Front Psychiatry       Date:  2021-07-09       Impact factor: 4.157

10.  A multi-site single blind clinical study to compare the effects of prolonged exposure, eye movement desensitization and reprocessing and waiting list on patients with a current diagnosis of psychosis and co morbid post traumatic stress disorder: study protocol for the randomized controlled trial Treating Trauma in Psychosis.

Authors:  Paul A J M de Bont; David P G van den Berg; Berber M van der Vleugel; Carlijn de Roos; Cornelis L Mulder; Eni S Becker; Ad de Jongh; Mark van der Gaag; Agnes van Minnen
Journal:  Trials       Date:  2013-05-23       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.